Oura is going public at $15.6 billion. Here's what the ring can actually prove.

A ring worth more than Lululemon

Oura kicked off its IPO roadshow on September 21, aiming to price its stock the week of September 28 on the Nasdaq under the ticker OURA. The Finnish smart ring maker, now headquartered in San Francisco, is selling 50 million shares priced between $40 and $44 each. At the top of that range, Oura's fully diluted valuation reaches roughly $15.6 billion, more than Prada or Lululemon are worth on public markets today, according to TechCrunch's read of the filing.

That number is built on real growth. Revenue for the nine months ending June 30, 2026 came in at $1.2 billion, up from $697.6 million a year earlier, and net income jumped to $60.8 million from just $1.6 million, according to Fortune's coverage of the offering. Oura expects to finish the fiscal year with 5.7 million paying members, up 96% year over year. CEO Tom Hale frames the company's edge as the size of its dataset: "AI and our particular take on it is going to be a pretty big moat. The data is actually the scarce resource here." Oura says it has collected nearly 42 billion hours of biometric data from people wearing its rings roughly 23 hours a day.

Who actually gets paid

Here is the part the headline valuation glosses over. Of the 50 million shares on offer, Oura itself is only selling 13.5 million. The remaining 36.5 million, about 73% of the deal, belong to existing investors and employees cashing out. Forerunner Ventures, an early backer that put in $28 million in a 2020 Series B round, is offloading nearly 80% of all the shareholder sold stock and stands to collect around $1.2 billion before fees.

Even the money Oura does keep isn't going far. The company expects to net about $532.6 million from its own share sale, and $526.4 million of that is earmarked to cover employee tax withholding obligations tied to vesting stock. That leaves roughly $6 million for anything resembling growth capital, at a company that already had $372 million in cash on hand at the end of June. This looks like a liquidity event for people who got in early, not a fundraise for a company short on runway.

The subscription pitch, and the asterisk

The story Oura wants Wall Street to buy is that it's a health intelligence platform, not a hardware company, one where AI turns a stream of biometric data into a recurring, high margin software business. Membership revenue did double year over year, to $240.5 million, and it carries an 89% gross margin. But that subscription business is still only about a fifth of total sales. Hardware, the one time sale of a ring priced from $299, makes up roughly 80% of revenue. A platform company that still sells mostly hardware is not necessarily a bad business. It just isn't the pure AI software story the valuation implies yet.

What the ring can prove, and what it can't

Oura's core claim, that it can tell you whether you were asleep or awake with real accuracy, holds up reasonably well. Independent validation studies comparing the ring against lab grade polysomnography find 90% to 96% agreement on basic sleep versus wake detection. It gets shakier on the more specific claims, breaking sleep into light, deep, and REM stages. There, accuracy runs 76% to 79%, which sounds unimpressive until you learn that human sleep technicians reviewing the same lab recordings only agree with each other about 82.6% of the time, according to a detailed breakdown of the validation literature. Sleep staging is a genuinely hard problem for machines and humans alike.

The bigger gap sits in Oura's more medical sounding ambitions. The company announced in October 2025 that it's pursuing FDA clearance for a blood pressure detection feature, which would flag users as having no signs, moderate signs, or major signs of high blood pressure, without a cuff. That trial only started enrolling in December 2025, and clearance isn't expected before late 2026 at the earliest. Right now, that feature doesn't exist as an approved product. It's a pitch deck line item. Our own reporting has found the same gap in other smart rings claiming to read blood sugar without a needle: the optical sensors in a ring can infer a lot, but inference is not the same as an FDA cleared measurement, and companies are increasingly happy to blur that line in marketing copy.

The Eli Lilly angle

One detail worth watching: Eli Lilly has indicated interest in buying up to $100 million of Oura shares in the offering. Lilly makes Zepbound and Mounjaro, and already partners with Oura on biometric tracking. A drugmaker wanting a stake in a device that logs sleep, heart rate, and activity for millions of people, many of them presumably on GLP-1s, says something about where pharma thinks the next competitive edge sits: not just the molecule, but the data trail showing whether it's working.

Our take

The sleep and activity tracking Oura built its reputation on is real, reasonably well validated, and worth something. The health intelligence platform pitch carrying a $15.6 billion valuation is getting ahead of what the ring is actually cleared to do, and the deal structure itself, insiders selling roughly three quarters of the stock, tells you this raise is mostly about liquidity for early backers, not fuel for the next phase of the company. If you already wear one, none of this changes what's on your finger. If you're watching the ticker, know what you're actually pricing.

Health Trend Wire holds no position in Oura and was not paid for this article. This is general information, not medical or financial advice.